Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review

  • ID: 1292063
  • SWOT Analysis
  • 55 pages
  • GlobalData
  • Alexion Pharmaceuticals
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Baxter International Inc
  • Genzyme Corp
  • MORE
Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Alexion Pharmaceuticals Inc (Alexion) focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic diseases, cancer, neurological and autoimmune disorders. The company’s marketed product portfolio includes Soliris (eculizumab) used for two indications paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS); Strensiq (asfotase alfa) for the treatment of hypophosphatasia (HPP)and Kanuma (sebelipase alfa) for the treatment of Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D). The company’s research and development activities focus on developing its lead product Soliris, for various other serious disease states. It also has other candidates in development targeting rare metabolic and inflammatory disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc Key Recent Developments

Apr 26, 2018: Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study
Apr 11, 2018: Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion
Feb 27, 2018: The Manton Center at Boston Children’s Hospital and Alexion Pharmaceuticals Partner in Artificial Intelligence Approaches to Rare Disease Diagnosis
Feb 08, 2018: Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018
Feb 05, 2018: Alexion Pharmaceuticals Names Judith A. Reinsdorf As Board Director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Baxter International Inc
  • Genzyme Corp
  • MORE
Section 1 - About the Company
  • Alexion Pharmaceuticals Inc - Key Facts
  • Alexion Pharmaceuticals Inc - Key Employees
  • Alexion Pharmaceuticals Inc - Key Employee Biographies
  • Alexion Pharmaceuticals Inc - Major Products and Services
  • Alexion Pharmaceuticals Inc - History
  • Alexion Pharmaceuticals Inc - Company Statement
  • Alexion Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Alexion Pharmaceuticals Inc - Business Description
  • Product Category: Kanuma
  • Overview
  • Performance
  • Product Category: Soliris
  • Overview
  • Performance
  • Product Category: Strensiq
  • Overview
  • Performance
  • Geographical Segment: Asia-Pacific
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Rest of World
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Alexion Pharmaceuticals Inc - Corporate Strategy
  • Alexion Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Alexion Pharmaceuticals Inc - Strengths
  • Alexion Pharmaceuticals Inc - Weaknesses
  • Alexion Pharmaceuticals Inc - Opportunities
  • Alexion Pharmaceuticals Inc - Threats
  • Alexion Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Alexion Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 26, 2018: Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study
  • Apr 11, 2018: Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion
  • Feb 27, 2018: The Manton Center at Boston Children’s Hospital and Alexion Pharmaceuticals Partner in Artificial Intelligence Approaches to Rare Disease Diagnosis
  • Feb 08, 2018: Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018
  • Jan 02, 2018: Alexion and Elliott Agree to Collaborate on Identifying a New Board Member
  • Nov 08, 2017: Alexion Appoints Francois Nader, M.D. to its Board of Directors
  • Oct 26, 2017: Alexion Reports Third Quarter 2017 Results
  • Sep 14, 2017: Alexion Adds Paul A. Friedman, M.D. to Its Board of Director
  • Sep 12, 2017: Alexion Announces Restructuring to Advance Corporate Strategy
  • Jul 27, 2017: Alexion Reports Second Quarter 2017 Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Alexion Pharmaceuticals Inc, Key Facts
  • Alexion Pharmaceuticals Inc, Key Employees
  • Alexion Pharmaceuticals Inc, Key Employee Biographies
  • Alexion Pharmaceuticals Inc, Major Products and Services
  • Alexion Pharmaceuticals Inc, History
  • Alexion Pharmaceuticals Inc, Subsidiaries
  • Alexion Pharmaceuticals Inc, Key Competitors
  • Alexion Pharmaceuticals Inc, Ratios based on current share price
  • Alexion Pharmaceuticals Inc, Annual Ratios
  • Alexion Pharmaceuticals Inc, Annual Ratios
  • Alexion Pharmaceuticals Inc, Annual Ratios
  • Alexion Pharmaceuticals Inc, Interim Ratios
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Alexion Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Alexion Pharmaceuticals Inc, Performance Chart (2013 - 2017)
  • Alexion Pharmaceuticals Inc, Ratio Charts
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ligand Pharmaceuticals Inc
  • Genzyme Corp
  • Baxter International Inc
  • Amgen Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll